Dosing & Uses
Dosage Forms & Strengths
tablet
- 250mg
Chronic Urinary Tract Infection
Indicated for chronic UTS caused by urea-splitting organisms
Initial: 12 mg/kg/day PO divided q6 -8hr on empty stomach
Maintenance: 250 mg PO q6-8hr; not to exceed 1.5 g/day
Renal Impairment
SCr 1.8-2.5 mg/dL [159-221 micromoles/L]: Dose q12hr; not to exceed 1 g/day
SCr >2.5 mg/dL [>221 micromoles/L]: Not recommended
Dosage Forms & Strengths
tablet
- 250mg
Chronic Urinary Tract Infection
Indicated for chronic UTS caused by urea-splitting organisms
Initial: 10 mg/kg/day PO divided q6-8hr on empty stomach; titrate to patient response
Chronic Urinary Tract Infection
Indicated for chronic UTS caused by urea-splitting organisms
Initial: 12 mg/kg/day PO divided q6-8hr on empty stomach
Maintenance: 250 mg PO q6-8hr; not to exceed 1.5 g/day
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (1)
- sodium picosulfate/magnesium oxide/anhydrous citric acid
acetohydroxamic acid decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
Minor (6)
- ethanol
acetohydroxamic acid, ethanol. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Temporary rash, flushing.
- ferric maltol
acetohydroxamic acid decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous fumarate
acetohydroxamic acid decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous gluconate
acetohydroxamic acid decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- ferrous sulfate
acetohydroxamic acid decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- rose hips
acetohydroxamic acid decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
>10%
Mild headache; first 48 hours (30%)
Anorexia (20-25%)
Malaise (20-25%)
Nausea (20-25%)
Vomiting (20-25%)
Anxiety (20%)
Confused (20%)
Depression (20%)
Involuntary quivering (20%)
Hemolytic anemia (15%)
<1%
Alopecia
Blood clot
Macular rash
Phlebitis
Warnings
Contraindications
Hypersensitivity
Pts. amenable to definitive surgery & antimicrobial agents, infection by non-urease producing organisms, urinary infections controlled by culture-specific antimicrobials, severe renal impairment (CrCl <20 mL/min &/or serum creatinine>2.5 mg/dL [221 umol/L]), inadequate contraception (females), pregnancy
Cautions
Always use with appropriate antimicrobial treatment
Potential teratogen
Pregnancy & Lactation
Pregnancy Category: X
Lactation: excretion in breast milk unknown/not recommended
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits bacterial urease, decreasing ammonia production
Does not acidify urine or have direct antibacterial effect
Pharmacokinetics
Absorption: Well-absorbed
Peak Plasma Time: 15 min -1 hr
Excretion: Urine (55% of oral dose unchanged)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Lithostat oral - | 250 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
